LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

444.43 1.01

Buy Sell

Overview

Share price change

24h

Current

Min

430.65

Max

450.31

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+59.74% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.4B 11B
Previous open	443.42
Previous close	444.43

News Sentiment

By Acuity

33%

67%

80 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 lut 2026, 22:36 UTC

Earnings

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 lut 2026, 22:32 UTC

Earnings

Woodside Energy Fiscal Year Net Profit Falls 24%

23 lut 2026, 23:58 UTC

Market Talk

Earnings

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 lut 2026, 23:58 UTC

Market Talk

Earnings

Global Energy Roundup: Market Talk

23 lut 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 lut 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 lut 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Crescent Capital Partners Owns 53% of ClearView Wealth

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 lut 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 lut 2026, 23:39 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 lut 2026, 23:31 UTC

Earnings

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 lut 2026, 23:31 UTC

Earnings

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 lut 2026, 23:27 UTC

Earnings

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 lut 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 lut 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 lut 2026, 22:31 UTC

Earnings

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 lut 2026, 22:24 UTC

Earnings

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Underlying Ebitda A$700.9 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 lut 2026, 22:21 UTC

Earnings

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 lut 2026, 22:21 UTC

Earnings

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 lut 2026, 22:20 UTC

Earnings

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

59.74% upside

12 Months Forecast

Average 694.9 USD 59.74%

High 964 USD

Low 529 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

80 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.